Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron (Nasdaq: GERN) has granted non-statutory stock options to newly hired employees as inducement awards. The company issued options to purchase an aggregate of 261,000 shares of Geron common stock on August 21, 2024, at an exercise price of $4.54 per share, equal to the closing price on the grant date. These options have a 10-year term and vest over four years, with 12.5% vesting after six months and the remainder vesting in equal installments over the following 42 months. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to Geron's 2018 Inducement Award Plan.
Geron (Nasdaq: GERN) ha concesso opzioni su azioni non statutarie ai nuovi assunti come premi di incentivazione. L'azienda ha emesso opzioni per l'acquisto di un totale di 261.000 azioni di azioni ordinarie di Geron il 21 agosto 2024, a un prezzo di esercizio di $4,54 per azione, equivalente al prezzo di chiusura nella data di concessione. Queste opzioni hanno un termine di 10 anni e si maturano nel corso di quattro anni, con il 12,5% che matura dopo sei mesi e il restante che matura in rate uguali nei successivi 42 mesi. Le concessioni sono state effettuate in conformità con la Regola di quotazione Nasdaq 5635(c)(4) e sono soggette al Piano di Premio di Incentivazione del 2018 di Geron.
Geron (Nasdaq: GERN) ha concedido opciones sobre acciones no estatutarias a los nuevos empleados como premios de incentivo. La empresa emitió opciones para comprar un total de 261,000 acciones de acciones ordinarias de Geron el 21 de agosto de 2024, a un precio de ejercicio de $4.54 por acción, que es igual al precio de cierre en la fecha de concesión. Estas opciones tienen un plazo de 10 años y se consolidan durante cuatro años, con un 12.5% consolidándose después de seis meses y el resto consolidándose en cuotas iguales durante los siguientes 42 meses. Las concesiones se realizaron de acuerdo con la Regla de Cotización Nasdaq 5635(c)(4) y están sujetas al Plan de Premios de Incentivo de 2018 de Geron.
Geron (Nasdaq: GERN)은 새로 채용된 직원들에게 유인 상으로 비법정 주식 옵션을 부여했습니다. 회사는 2024년 8월 21일에 Geron 일반 주식 261,000주를 구매할 수 있는 옵션을 발행하였으며, 행사 가격은 $4.54 per share로, 이는 부여 날짜의 종가와 같습니다. 이 옵션은 10년의 기간을 가지며, 4년에 걸쳐 유효합니다. 첫 12.5%는 6개월 후에 유효해지고, 나머지는 다음 42개월 동안 동일한 할부로 유효해집니다. 이 부여는 Nasdaq 상장 규칙 5635(c)(4)에 따라 이루어졌으며, Geron의 2018 유인 상 수여 계획의 적용을 받습니다.
Geron (Nasdaq: GERN) a accordé des options d'achat d'actions non statutaires à de nouveaux employés en tant que primes d'incitation. L'entreprise a émis des options d'achat d'un total de 261 000 actions ordinaires de Geron le 21 août 2024, à un prix d'exercice de $4,54 par action, égal au prix de clôture à la date d'attribution. Ces options ont une durée de 10 ans et se libèrent sur quatre ans, avec 12,5 % se libérant après six mois et le reste se libérant en versements égaux sur les 42 mois suivants. Les attributions ont été effectuées conformément à la règle de cotation Nasdaq 5635(c)(4) et sont soumises au plan de primes d'incitation de Geron de 2018.
Geron (Nasdaq: GERN) hat nicht-statutäre Aktienoptionen als Anreizpreise an neu eingestellte Mitarbeiter vergeben. Das Unternehmen gab am 21. August 2024 Optionen zum Kauf von insgesamt 261.000 Aktien der Geron-Stammaktien aus, zu einem Ausübungspreis von $4,54 pro Aktie, der dem Schlusskurs am Tag der Gewährung entspricht. Diese Optionen haben eine Laufzeit von 10 Jahren und verfallen über vier Jahre, wobei nach sechs Monaten 12,5 % verfallen und der Rest in gleichen Raten über die folgenden 42 Monate verfallen. Die Gewährungen erfolgten gemäß Nasdaq-Listing-Regel 5635(c)(4) und unterliegen dem Anreizpreisplan von Geron aus dem Jahr 2018.
- Geron is expanding its workforce, potentially indicating business growth
- The company is able to offer competitive compensation packages to attract new talent
- Granting of stock options may lead to potential dilution for existing shareholders
The stock options were granted on August 21, 2024, at an exercise price of
About Geron
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO™ (imetelstat) is FDA-approved for the treatment of adult patients with lower-risk MDS with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240822066654/en/
Aron Feingold
Vice President, Investor Relations and Corporate Communications
Kristen Kelleher
Associate Director, Investor Relations and Corporate Communications
investor@geron.com
media@geron.com
Source: Geron Corporation
FAQ
How many stock options did Geron (GERN) grant to new employees on August 21, 2024?
What is the exercise price of the stock options granted by Geron (GERN) on August 21, 2024?
What is the vesting schedule for the stock options granted by Geron (GERN) to new employees?
Under which Nasdaq rule did Geron (GERN) grant these inducement awards?
